Clinical, immunological and virological evolution in patients with CD4 T-cell count above 500/mm3: Is there a benefit to treat with highly active antiretroviral therapy (HAART)?

European Journal of Epidemiology

Volumn 19, Issue 6, 2004, Pages 597-604

  Piroth, Lionel ^a,d   Binquet, Christine ^b   Buisson, Marielle ^a   Kohli, Evelyne ^b   Duong, Michel ^a   Grappin, Michèle ^a   Abrahamowicz, Michal ^c   Quantin, Catherine ^b   Portier, Henri ^a   Chavanet, Pascal ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b HÔPITAL DU BOCAGE   (France)

^c MONTREAL GENERAL HOSPITAL   (Canada)

^d Medical University of Dijon   (France)

Author keywords

Antiretroviral therapy; CD4 T cell count; HIV; HIV viral load

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; SEXUAL TRANSMISSION; T LYMPHOCYTE; TREATMENT OUTCOME; VIRAL CONTAMINATION; VIRUS INFECTION; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; VIRAL LOAD;

EID: 3442877506     PISSN: 03932990     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:EJEP.0000032378.98991.59     Document Type: Article

References (47)

1. Ho D. Time to hit HIV, early and hard. N Engl J Med 1995; 333: 450-451.
2. BHIVA guidelines co-ordinating committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 349: 1086-1092.
3. Gazzard B, Moyle G. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998; 352: 314-316.
4. Carpenter C, Cooper D, Fischl M, et al. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel. JAMA 2000; 283: 381-390.
5. Boscardin W, Taylor J, Law N. Longitudinal models for AIDS marker data. Stat Meth Med Res 1998; 7: 13-27.
6. Delfraissy J. Tests de résitance aux antirétroviraux. In: Médecine-Sciences F (ed), Prise en charge thérapeutique des personnes infectées par le VIH, Paris: Recommandations du groupe d'experts, 1999: 35-50.
7. O'Brien W, Hartigan P, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affair Cooperative Study Group on AIDS. N Engl J Med 1996; 334: 426-431.
8. O'Brien W, Hartigan P, Daar E, Simberkoff M, Hamilton J. Changes in plasma HIV RNA levels and CD4+ lymphocyte count predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 1997; 126: 939-945.
9. Chêne G, Binquet C, Moreau J, et al. Changes in CD4+ cell count and the risk of opportunisitc infection or death after highly active antiretroviral treatment. AIDS 1998; 12: 2313-2320.
10. Staszewski S, DeMasi R, Hill A, Dawson D. HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors. AIDS 1998; 12: 1991-1997.
11. Cozzi Lepri A, Katzenstein T, Ullum H, et al. The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. AIDS 1998; 12: 1639-1643.
12. Miller V, Mocroft A, Reiss P, et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: Results from the EuroSIDA study. Ann Intern Med 1999; 130: 570-577.
13. Casari S, Donisi A, Paraninfo G, et al. Prognostic factors correlated with survival in AIDS patients. Eur J Epidemiol 1999; 15: 691-698.
14. Thiébaut R, Morlat P, Jacqmin-Gadda H, et al. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. AIDS 2000; 14: 971-978.
15. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occuring after initiation of potent antiretroviral therapy: The Swiss HIV cohort study. JAMA 1999; 282: 2220-2226.
16. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Lancet 1999; 353: 863-868.
17. Romeu J, Balague M, Ruiz L, et al. Short-term risk for AIDS-indicator diseases predicted by plasma HIV-1 RNA and CD4+ lymphocytes. Scand J Infect Dis 1999; 31: 37-42.
18. d'Arminio Monforte A, Testori V, Adorni F, et al. CD4 cell count at the third month of HAART may predict clinical failure. AIDS 1999; 13: 1669-1676.
19. Anastos K, Kalish L, Hessol N, et al. The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1 infected women: Results of the interagency HIV study. AIDS 1999; 13: 1717-1726.
20. Maher K, Klimas N, Fletcher M, et al. Disease progression, adherence, and response to protease inhibitor therapy for HIV infection in an urban veterans affairs medical center. J Acq Immun Def Synd 1999; 22: 358-363.
21. Perneger T, Abrahamovicz M, Bartlett G, Yerly S. Time-dependence of survival predictions based on markers of HIV disease. Swiss HIV cohort study. J Investig Med 2000; 48: 207-212.
22. Garcia F, Romeu J, Grau I, et al. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: The Spanish Earth-1 study. AIDS 1999; 13: 2377-2388.
23. Mocroft A, Gill M, Davidson W, Phillips A. Predictors of a viral response and subsequent treatment failure in patients with HIV starting a protease inhibitor. AIDS 1998; 12: 2161-2167.
24. Fätkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997; 11: F113-F116.
25. Lucas G, Chaisson R, Moore R. Highly active anti-retroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131: 81-87.
26. Deeks S, Hecht F, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy. AIDS 1999; 13: F35-F43.
27. Staszewski S, Miller V, Sabin C, et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS 1999; 13: 367-373.
28. Wit F, van Leeuwen R, Weverling G, et al. Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999; 179: 790-798.
29. Paredes R, Mocroft A, Kirk O, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe. Arch Intern Med 2000; 160: 1123-1132.
30. Grabar S, Pradier C, Le Corfec E, et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS 2000; 14: 141-149.
31. Yerly S, Kaiser L, Perneger T, et al. Time of initiation of antiretroviral therapy: Impact on HIV-1 viraemia. AIDS 2000; 14: 243-249.
32. Rizzardi G, De Boer R, Hoover S, et al. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. J Clin Invest 2000; 105: 777-782.
33. Re M, Ramazzotti E, Manfredi R, et al. Viral load trend in HIV-1 seropositive patients with different CD4 cell counts before starting HAART. J Clin Virol 2000; 17: 5-11.
34. Casado J, Perez-Elias M, Antela A, et al. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS 1998; 12: F131-F135.
35. Kaufmann G, Bloch M, Zaunders J, Smith D, Cooper D. Long-term immunological response in HIV-1 infected subjects receiving potent antiretroviral therapy. AIDS 2000; 14: 959-969.
36. Mellors J, Munoz A, Giorgi J, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV infection. Ann Intern Med 1997; 126: 946-954.
37. Sabin C, Devereux H, Phillips A, et al. Course of viral load throughout HIV-1 infection. J Acq Immun Def Synd 2000; 23: 172-177.
38. Bonfanti P, Valsecchi L, Parazzini F, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: A cohort study. J Acq Immun Def Synd 2000; 23: 236-245.
39. Ferrer E, Consiglio E, Podzamczer D, et al. Analysis of the discontinuation of protease inhibitor therapy in routine clinical practice. Scand J Infect Dis 1999; 31: 495-499.
40. Singh N, Berman S, Swindells S, et al. Adherence of human immunodeficency virus-infected patients to antiretroviral therapy. Clin Infect Dis 1999; 29: 824-830.
41. Haubrich R, Little S, Currier J, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologie and immunologic response. AIDS 1999; 13: 1099-1107.
42. Opravil M, Cone R, Fischer M, et al. Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoïd tissued: A randomized trial of double versus triple therapy. J Acq Immun Def Synd Hum Retrovirol 2000; 23: 17-25.
43. d'Aminio Monforte A, Cozzi Lepri A, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral patients. AIDS 2000; 14: 499-507.
44. Erb P, Battegay M, Zimmerli W, Rickenbach M, Egger M. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Arch Intern Med 2000; 160: 1134-1140.
45. Deeks S, Barbour J, Martin J, Swanson M, Grant R. Sustained CD4+ T cell response after virologie failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000; 181: 946-953.
46. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295-1300.
47. Easterbrook P, Yu L, Goetghebeur E, Boag F, McLean K, Gazzard B. Ten-year trend in CD4 cell counts at HIV and AIDS diagnosis in a London HIV clinic. AIDS 2000; 14: 561-571.